Isoprostane/FMD Study The Effect of Protein Kinase C (PKC) β Specific Inhibitor LY333531 on Oxidant Stress in Patients With Type 2 Diabetes Mellitus
Clinical trial NCT00552227 · COMPLETED
Trial details
- NCT number
- NCT00552227
- Sponsor
- Chromaderm, Inc.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2002-09-01
- Enrollment
- 48
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.